Summary：**BreathEaseX Launches Sublingual Lung Spray, Offering Instant Relief with CardioEaseX Formula** Br**BreathEaseX Launches Sublingual Lung Spray, Offering Instant Relief with CardioEaseX Formula**
BreathEaseX today unveiled a new sublingual lung spray designed to deliver rapid respiratory support through its proprietary CardioEaseX formula. The product, aimed at individuals experiencing occasional breathlessness or mild bronchial irritation, promises to act within seconds by absorbing directly under the tongue and targeting pulmonary pathways. Company officials said the launch responds to growing consumer demand for non‑inhaled, fast‑acting alternatives to traditional inhalers and nebulizers. Early clinical trials showed a statistically significant improvement in peak expiratory flow rates among participants using the spray compared to placebo, reinforcing the brand’s claim of instant relief.
The key development centers on the CardioEaseX blend, which combines a low‑dose bronchodilator with antioxidant‑rich plant extracts and a proprietary lipid carrier that enhances sublingual bioavailability. BreathEaseX highlighted that the spray avoids the propellants and steroids found in many metered‑dose inhalers, reducing the risk of oral thrush and systemic side effects. The product will be available over‑the‑counter in select pharmacies and online retailers starting next month, with a starter kit priced at $29.99. Marketing materials emphasize convenience for active lifestyles, positioning the spray as a “pocket‑sized rescue” for athletes, commuters, and seniors who experience transient breathing discomfort.
Industry analysts note that the sublingual delivery route is gaining traction in the respiratory market as consumers seek alternatives that bypass lung deposition challenges. According to a recent report by Global Respiratory Insights, the global market for non‑inhaled respiratory aids is projected to grow at a CAGR of 6.4% through 2030, driven by rising awareness of device‑free therapies and an
